Audio By Carbonatix
An American biotech company says it created a coronavirus vaccine three hours after getting access to the virus' genetic sequence in mid-January, and now scientists are racing to get the vaccine on the market in record time.
Inovio Pharmaceuticals is based in Pennsylvania, but scientists in its laboratory in San Diego made the discovery.
"We were able to rapidly construct our vaccine in a matter of about three hours once we had the DNA sequence from the virus available because of the power of our DNA medicine platform," Dr. J. Joseph Kim, Inovio's president and CEO, told FOX Business. "Our goal is to start phase one human testing in the U.S. early this summer."
China has reported 254 new daily deaths and a spike in new daily virus cases of 15,152, after new methodology was applied in the hardest-hit province of Hubei as to how cases are categorised.
Medical workers treat patients in the isolated intensive care unit at a hospital in Wuhan in central China's Hubei province Thursday.
Inovio's stock jumped to $5.32 a share a few days after the company announced it was selected to work on a coronavirus vaccine.
The American company is partnering with Beijing Advaccine, a Chinese company, to work on the vaccine. Inovio also received $9 million to work on the vaccine from the Coalition for Epidemic Preparedness Innovations, which is backed by billionaire Bill Gates.
"We’ve done this many, many times before. The most relevant was building our vaccine against MERS virus, which is a coronavirus in the same family as COVID-19," Kim said.
Inovio took a vaccine for Zika virus from construct design to human testing in the U.S. in less than seven months, Kim said.
"We’re planning to beat our own record," he said. "Maybe we could do that in close to half that time."
Inovio is building a coalition for the "war" against COVID-19 that will require scaling up to thousands upon thousands of doses, Kim said.
Another U.S. company, Maryland-based Novavax, is aiming to make a coronavirus vaccine in as little as three months, although such vaccines can take years to develop. The company made an Ebola vaccine in 90 days.
Medical workers treat patients in the isolated intensive care unit at a hospital in Wuhan in central China's Hubei province Thursday.
Inovio's stock jumped to $5.32 a share a few days after the company announced it was selected to work on a coronavirus vaccine.
The American company is partnering with Beijing Advaccine, a Chinese company, to work on the vaccine. Inovio also received $9 million to work on the vaccine from the Coalition for Epidemic Preparedness Innovations, which is backed by billionaire Bill Gates.
"We’ve done this many, many times before. The most relevant was building our vaccine against MERS virus, which is a coronavirus in the same family as COVID-19," Kim said.
Inovio took a vaccine for Zika virus from construct design to human testing in the U.S. in less than seven months, Kim said.
"We’re planning to beat our own record," he said. "Maybe we could do that in close to half that time."
Inovio is building a coalition for the "war" against COVID-19 that will require scaling up to thousands upon thousands of doses, Kim said.
Another U.S. company, Maryland-based Novavax, is aiming to make a coronavirus vaccine in as little as three months, although such vaccines can take years to develop. The company made an Ebola vaccine in 90 days.DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.
DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.
Latest Stories
-
Kpebu doubts claims that Akufo-Addo administration interfered with Special Prosecutor
29 minutes -
It’s difficult to believe everything the OSP says – Manasseh Awuni
47 minutes -
I would’ve blocked Ofori-Atta from leaving Ghana if I were Special Prosecutor – Martin Kpebu
1 hour -
I’m headed for public office, but not the OSP role – Martin Kpebu
2 hours -
I will only submit my allegations to a board, not the OSP’s subordinates – Martin Kpebu
2 hours -
‘I’m still a bit traumatised’ – Martin Kpebu recounts alleged abuse during OSP arrest
2 hours -
Martin Kpebu dismisses claims he seeks to become Special Prosecutor
2 hours -
Martin Kpebu denies verbally abusing OSP officers, says allegations are fabricated
2 hours -
Mahama arrives in Doha for 2025 Doha Forum engagements
2 hours -
Milo U13 Champs: Ahafo’s Adrobaa set for thrilling final with Franko International of Western North
5 hours -
Ghana’s HIV crisis: Stigma drives new infections as AIDS Commission bets on AI and six-month injectables
6 hours -
First Ladies unite in Accra to champion elimination of mother-to-child HIV, Syphilis, and Hepatitis B transmission
6 hours -
US Supreme Court agrees to hear case challenging birthright citizenship
7 hours -
Notorious Ashaiman robber arrested in joint police operation
8 hours -
Judge sets key dates after video evidence hurdle in Nana Agradaa appeal case
9 hours
